Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | See remarks | August 26, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date August 26, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 223,657 |
Reported balance
After 2026-08-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 4,508 · Balance 223,657 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,102 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 6,102 shares underlying restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2023 Filed Mar 28, 2023 20:52 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 297 | $15.36 | $4,561.92 |
DisclosureSEC source: 0001209191-23-021423 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,243 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on March 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 135,018 shares underlying RSUs. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:29 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 740 | $21.56 | $15,954.40 |
DisclosureSEC source: 0001209191-23-005706 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,540 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,454 shares of restricted stock units ("RSUs") on January 27, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 136,010 shares underlying RSUs. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:36 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 97,630 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004135 · doc4.xml · derivative · entry 3 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,630 Underlying: Common Stock · 97,630 shares Expires 2033-01-16 F4 · derivative.exercise_date: Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:36 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 97,630 | $0.00 Strike: $20.45 | $0.00 |
DisclosureSEC source: 0001209191-23-004135 · doc4.xml · derivative · entry 2 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,630 Underlying: Common Stock · 97,630 shares Expires 2033-01-16 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 20, 2023 01:36 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 97,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004135 · doc4.xml · nonDerivative · entry 1 Rahmer Peter · CIK 0001959229 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,280 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. F2 · balance_after: Includes 138,464 shares underlying RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.